David Chang, MD,MPH,FACR
Chief Medical Officer
Cabaletta Bio
Bryn Mawr, Pennsylvania, United States
Disclosure information not submitted.
Iain McInnes, PhD, FRCP
Professor of Medicine and Rheumatology
University of Glasgow
Glasgow, United Kingdom
Disclosure information not submitted.
During this interactive session, our speakers will highlight emergent clinical and translational data in the field of CAR T cell therapy that could define an immune RESET for patients with certain autoimmune diseases. Speakers will also provide an overview of the distinguishing features of CABA-201, a CD19-CAR T cell therapy candidate, and the RESETâ„¢ Ph 1/2 clinical program in several autoimmune diseases, including lupus, myositis, and systemic sclerosis. Developed and offered by Cabaletta Bio. Not an official program of the ACR.
Non-CME